Grey Wolf Therapeutics closes oversubscribed $50 million Series B financing expansion led by ICG Life Sciences team to accelerate and expand first-of-its-kind antigen modulation technology.
Amount Raised
$50 Million
Round Type
Series B
MiltonBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
Grey Wolf Therapeutics has closed an oversubscribed $50 million Series B financing expansion, bringing the total amount of Series B funds raised to $99 million. The funding round was led by ICG's Life Sciences team and included further investment from existing investors Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises and British Patient Capital. The proceeds will support the broadening scope of the company's ongoing Phase 1/2 clinical trial of its lead immuno-oncology candidate, GRWD5769, in a range of solid tumor types, as well as expand research and development (R&D) for its versatile antigen modulation approach into treatments for autoimmune disease indications.
Quick answer
Grey Wolf Therapeutics raised $50 Million in a Series B round, dated May 23, 2024. Investors: British Patient Capital, Oxford Science Enterprises, Earlybird Venture Capital, Canaan, Andera Partners, Pfizer Ventures and ICG Life Sciences. Grey Wolf Therapeutics is based in Milton, Oxfordshire, United Kingdom.
- How much did Grey Wolf Therapeutics raise?
- Grey Wolf Therapeutics raised $50 Million in a Series B round on May 23, 2024.
- Who invested in Grey Wolf Therapeutics?
- British Patient Capital, Oxford Science Enterprises, Earlybird Venture Capital, Canaan, Andera Partners, Pfizer Ventures and ICG Life Sciences are named as investors in this round.
- What does Grey Wolf Therapeutics do?
- Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of..
- Where is Grey Wolf Therapeutics based and how big is it?
- Grey Wolf Therapeutics is based in Milton, Oxfordshire, United Kingdom. Fundz records about 42 employees.
- Who are the decision-makers at Grey Wolf Therapeutics?
- Fundz holds 1 contact at Grey Wolf Therapeutics, including the Co-Founder & CSO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Grey Wolf Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Scorpion Therapeutics raised $126M on July 1, 2024.
- N-Power Medicine raised $72M (Series B) on July 1, 2024.
- Cognito Therapeutics raised $10M on June 18, 2024.
- Aptose Biosciences raised $4.4M (Seed) on June 3, 2024.
- Novocure raised $400M (Debt Financing) on May 2, 2024.
- Scipher Medicine raised $25M on May 2, 2024.
Who to call at Grey Wolf Therapeutics, and when
A new round usually means Grey Wolf Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Grey Wolf Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Grey Wolf Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Grey Wolf Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Grey Wolf Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGrey Wolf Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.